Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
19.72
USD
|
+2.44%
|
|
+13.07%
|
+227.03%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
82.31
|
56.12
|
143.9
|
766.7
|
-
|
-
|
Enterprise Value (EV)
1 |
-24.41
|
-11.47
|
143.9
|
556.7
|
503.7
|
476.7
|
P/E ratio
|
-2.53
x
|
-1.27
x
|
-2.52
x
|
-9.31
x
|
-7.44
x
|
-7.27
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
307
x
|
-
|
125
x
|
EV / Revenue
|
-
|
-
|
-
|
223
x
|
-
|
77.6
x
|
EV / EBITDA
|
0.88
x
|
0.26
x
|
-2.53
x
|
-6.79
x
|
-4.77
x
|
-5.39
x
|
EV / FCF
|
-
|
0.3
x
|
-
|
-8.92
x
|
-5.25
x
|
-4.68
x
|
FCF Yield
|
-
|
332%
|
-
|
-11.2%
|
-19%
|
-21.4%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
16,867
|
17,215
|
23,857
|
38,878
|
-
|
-
|
Reference price
2 |
4.880
|
3.260
|
6.030
|
19.72
|
19.72
|
19.72
|
Announcement Date
|
3/3/22
|
3/2/23
|
3/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
2.5
|
-
|
6.14
|
EBITDA
1 |
-
|
-27.84
|
-44.79
|
-56.75
|
-81.94
|
-105.6
|
-88.4
|
EBIT
1 |
-
|
-27.84
|
-44.8
|
-56.76
|
-77.28
|
-105.8
|
-122.5
|
Operating Margin
|
-
|
-
|
-
|
-
|
-3,091.05%
|
-
|
-1,995.66%
|
Earnings before Tax (EBT)
1 |
-
|
-27.8
|
-43.94
|
-54.42
|
-73.9
|
-103.7
|
-120.3
|
Net income
1 |
-14.4
|
-27.8
|
-43.94
|
-54.42
|
-73.9
|
-103.7
|
-120.3
|
Net margin
|
-
|
-
|
-
|
-
|
-2,955.9%
|
-
|
-1,959.23%
|
EPS
2 |
-5.220
|
-1.930
|
-2.560
|
-2.390
|
-2.119
|
-2.652
|
-2.714
|
Free Cash Flow
1 |
-
|
-
|
-38.06
|
-
|
-62.4
|
-95.9
|
-102
|
FCF margin
|
-
|
-
|
-
|
-
|
-2,496%
|
-
|
-1,660.42%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/19/21
|
3/3/22
|
3/2/23
|
3/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
2.5
|
-
|
-
|
EBITDA
1 |
-
|
-
|
-9.619
|
-11.56
|
-11.88
|
-11.73
|
-11.96
|
-15.64
|
-13.58
|
-15.57
|
-15.66
|
-16.82
|
-18.16
|
-19.45
|
-
|
EBIT
1 |
-6.355
|
-8.794
|
-9.62
|
-11.57
|
-11.88
|
-11.73
|
-11.96
|
-15.64
|
-13.58
|
-15.57
|
-16.38
|
-17.65
|
-19.19
|
-20.57
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-767.66%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-6.345
|
-8.773
|
-9.597
|
-11.41
|
-11.6
|
-11.34
|
-11.46
|
-15
|
-12.93
|
-15.03
|
-15.92
|
-16.36
|
-17.96
|
-19.4
|
-
|
Net income
1 |
-6.345
|
-8.773
|
-9.597
|
-11.41
|
-11.6
|
-11.34
|
-11.46
|
-15
|
-12.93
|
-15.03
|
-15.92
|
-16.36
|
-17.96
|
-19.4
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-718.32%
|
-
|
-
|
EPS
2 |
-0.3800
|
-0.5200
|
-0.5600
|
-0.6700
|
-0.6800
|
-0.6600
|
-0.5600
|
-0.6500
|
-0.5500
|
-0.6200
|
-0.4923
|
-0.4765
|
-0.4594
|
-0.5734
|
-0.5700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
3/3/22
|
5/5/22
|
8/4/22
|
11/3/22
|
3/2/23
|
5/9/23
|
8/3/23
|
11/2/23
|
3/12/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
107
|
67.6
|
-
|
210
|
263
|
290
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-38.1
|
-
|
-62.4
|
-95.9
|
-102
|
ROE (net income / shareholders' equity)
|
-
|
-35.5%
|
-53.3%
|
-
|
-55%
|
-76.7%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.02
|
-
|
-
|
-
|
2.5
|
2.5
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
40.72%
|
Announcement Date
|
2/19/21
|
3/3/22
|
3/2/23
|
3/12/24
|
-
|
-
|
-
|
Last Close Price
19.72
USD Average target price
42.57
USD Spread / Average Target +115.88% Consensus |
1st Jan change
|
Capi.
|
---|
| +227.03% | 767M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|